Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Preclinical Animal Models
100%
JAK Inhibitors
100%
Janus Kinase 1 (JAK1)
60%
Baricitinib
60%
Donor T Cell
40%
Antigen-presenting Cells
40%
Janus Kinase 2 (JAK2)
40%
Ruxolitinib
40%
Immune Reconstitution
20%
Hematological Malignancies
20%
T Cells
20%
Significant Risk Factors
20%
Regulatory T Cells
20%
Malignancy
20%
Highly Effective
20%
Donor Graft
20%
Interferon Receptor
20%
Non-cancer
20%
Recipient Cells
20%
CXCR3
20%
Autoreactive T Cells
20%
T-bet
20%
CD80
20%
Therapeutic Benefits
20%
JAK2 Inhibitor
20%
T Cell Reconstitution
20%
JAK3
20%
IL-6 Receptor Signaling
20%
Immunology and Microbiology
Hematopoietic Cell
100%
Mouse Model
100%
Graft-Versus-Host Disease
100%
Cell Transplantation
100%
T Cell
60%
Antigen-Presenting Cell
40%
Immune Reconstitution
20%
Mediator
20%
Regulatory T Cell
20%
Interleukin 6
20%
CXCR3
20%
Interferon-Gamma Receptor
20%
CD80
20%
Alloreactive T Cell
20%